Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
UNI-DUR vs ALBUTEROL SULFATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
UNI-DUR (theophylline) inhibits phosphodiesterase enzymes, leading to increased intracellular c AMP levels. This causes bronchodilation, anti-inflammatory effects (reduced eosinophil infiltration, decreased cytokine release), and enhanced diaphragmatic contractility. It also acts as a weak adenosine receptor antagonist.
Beta-2 adrenergic receptor agonist resulting in bronchodilation via increased cyclic AMP synthesis and smooth muscle relaxation.
Treatment of asthma (chronic stable and acute exacerbations),Chronic obstructive pulmonary disease (COPD) maintenance therapy,Apnea of prematurity (off-label),Ureteral colic (off-label)
Treatment of bronchospasm in patients with reversible obstructive airway disease,Prophylaxis of exercise-induced bronchospasm,Acute asthma exacerbation (off-label)
200-400 mg orally every 12 hours; maximum 800 mg daily.
2 puffs (90 mcg/puff) via metered-dose inhaler q4-6h as needed; or 2.5 mg via nebulization q4-6h as needed
Terminal elimination half-life 24-36 hours; prolonged in renal impairment (up to 90 hours).
Terminal elimination half-life is 3.8–6 hours after inhalation; in patients with hepatic impairment, half-life may be prolonged up to 8 hours.
Theophylline is primarily metabolized in the liver by cytochrome P450 enzymes CYP1A2 (major) and CYP2E1, CYP3A4 (minor). It undergoes N-demethylation and oxidation to form metabolites (1-methylxanthine, 3-methylxanthine, 1,3-dimethyluric acid). Approximately 10% is excreted unchanged in urine.
Extensively metabolized via catechol-O-methyltransferase (COMT) and conjugation; hepatic metabolism also occurs.
Primarily renal (70-80%) as unchanged drug and metabolites; 10-15% fecal.
Approximately 72% of an inhaled dose is recovered in urine as unchanged drug and metabolites (28% as sulfate conjugate) within 24 hours; fecal elimination accounts for less than 10%.
95% bound to albumin.
Approximately 10% bound to plasma proteins (primarily albumin).
Vd 0.2-0.3 L/kg; indicates distribution primarily in extracellular fluid.
Mean Vd is 1.6–2.0 L/kg after IV administration, indicating extensive distribution into tissues.
Oral: 85-95% (immediate-release); 70-80% (extended-release).
Inhalation: 10–20% of the dose reaches the lungs systemically; oral: approximately 50% (first-pass metabolism; active metabolite formed).
GFR 30-50 m L/min: 200 mg every 12 hours; GFR <30 m L/min: 200 mg every 24 hours; hemodialysis: 200 mg after dialysis.
No dose adjustment required for any degree of renal impairment
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg every 12 hours; Child-Pugh C: 200 mg every 24 hours.
No dose adjustment required for any Child-Pugh class (A, B, or C)
5-10 mg/kg orally every 12 hours; maximum 400 mg daily.
Children 2-12 years: 1-2 puffs (90 mcg/puff) via MDI q4-6h as needed; or 0.15 mg/kg (min 1.25 mg, max 2.5 mg) via nebulization q4-6h as needed
Initiate at 200 mg every 12 hours; increase cautiously, monitor renal function.
No specific dose adjustment; use lowest effective dose due to increased sensitivity to beta-adrenergic effects; monitor for tachycardia and tremor
WARNING: Life-threatening adverse events, including seizures, cardiac arrhythmias, and respiratory arrest, can occur with theophylline toxicity. Serum theophylline levels must be monitored closely, and dosing adjusted to maintain therapeutic range (5-15 mcg/m L). Concurrent use with other xanthines (e.g., caffeine) is contraindicated.
No FDA black box warning.
Therapeutic drug monitoring required due to narrow therapeutic index. Caution in patients with hepatic impairment, heart failure, pneumonia, elderly, and fever (prolonged half-life). Drug interactions with CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) and inducers (e.g., smoking, rifampin). Seizure risk at high levels. Cardiotoxicity (atrial/ventricular arrhythmias).
Paradoxical bronchospasm may occur with excessive use,Cardiovascular effects (tachycardia, arrhythmia) especially with concurrent beta-blocker use,Hypokalemia risk with high doses,Use caution in patients with hyperthyroidism, diabetes, or seizure disorders
Hypersensitivity to theophylline or any component. Concurrent use with ephedrine or other xanthines. Active seizure disorder (relative). Uncontrolled cardiac arrhythmias. Severe hepatic impairment.
History of hypersensitivity to albuterol or any component
Food does not affect absorption significantly; however, consistent dietary caffeine intake may increase side effects. A high-protein, low-carbohydrate diet can decrease theophylline clearance; avoid drastic dietary changes.
No significant food interactions reported with albuterol sulfate. However, caffeine-containing foods or beverages (e.g., coffee, tea, cola) may theoretically potentiate stimulant effects such as increased heart rate or nervousness, though clinical significance is minimal. Patients should maintain normal dietary habits unless directed otherwise by their healthcare provider.
Pregnancy Category C. First trimester: no adequate studies, potential risk based on animal data. Second and third trimesters: may cause fetal harm including decreased uterine blood flow, growth restriction, and premature labor inhibition. Avoid use unless benefit outweighs risk.
Pregnancy category C. Inhaled albuterol is not associated with major congenital malformations in first trimester. Second and third trimester use may cause fetal tachycardia, hyperglycemia, and transient neonatal hypoglycemia. High-dose intravenous or oral use increases risk of uterine relaxation, maternal tachycardia, and potential placental hypoperfusion.
Excreted in human milk; M/P ratio not established. Potential for serious adverse reactions in nursing infants. Decision to discontinue nursing or drug based on importance to mother.
Present in breast milk in low concentrations (M/P ratio unknown but likely <1). Limited data indicate no adverse effects in nursing infants. The American Academy of Pediatrics considers inhaled albuterol compatible with breastfeeding. Use lowest effective dose.
No standard dose adjustments. Increased clearance and volume of distribution during pregnancy may require dose titration based on clinical response and serum drug levels if applicable.
No routine dose adjustment required for inhaled albuterol. Pharmacokinetic changes in pregnancy (increased clearance, decreased free fraction) do not necessitate adjustment for standard inhaled doses. For continuous nebulization or high-dose use, monitor maternal heart rate and consider dose reduction if significant tachycardia occurs.
UNI-DUR (theophylline extended-release) requires monitoring of serum theophylline concentrations to maintain efficacy and avoid toxicity; therapeutic range is 5-15 mcg/m L. Avoid use in patients with active peptic ulcer disease or seizure disorders. Dosage adjustments needed in hepatic impairment, heart failure, and with concurrent use of drugs that affect CYP1A2 and CYP3A4.
Albuterol sulfate is a short-acting beta-2 agonist (SABA) used for acute bronchospasm relief. Onset of action is within 5-15 minutes by inhalation. Monitor for paradoxical bronchospasm, which may require discontinuation. Not indicated for maintenance therapy in asthma without concomitant inhaled corticosteroid. Can cause hypokalemia, especially at high doses; monitor potassium in at-risk patients. Use with caution in patients with cardiovascular disease, as beta-agonists can increase heart rate and blood pressure. Albuterol is pregnancy category C; use only if clearly needed. Nebulized albuterol is preferred for acute severe asthma exacerbations. Inhaled albuterol may be combined with ipratropium for acute exacerbations.
Take UNI-DUR exactly as prescribed, at the same time each day, with or without food.,Do not crush or chew the tablets; swallow whole.,Avoid smoking and limit caffeine intake as they can alter theophylline levels.,Report symptoms of toxicity such as nausea, vomiting, insomnia, palpitations, or seizures.,Do not change brands or formulations without consulting your healthcare provider.
Use albuterol exactly as prescribed; it is for quick relief of wheezing and shortness of breath, not for daily prevention unless directed.,Rinse your mouth with water after using the inhaler to prevent dry mouth and throat irritation.,Shake the inhaler well before each use and prime it if not used for more than 2 weeks.,If you need more than 2 puffs twice a week for symptom relief, consult your doctor as your asthma may not be well-controlled.,Seek emergency medical help if you have worsening symptoms, chest tightness, or if the medication does not provide relief.,Avoid spraying albuterol into your eyes; if accidental contact occurs, rinse with water for several minutes.,Inform your doctor if you are pregnant, breastfeeding, or have heart problems, high blood pressure, seizures, or diabetes.,Store the inhaler at room temperature away from heat and open flame; do not puncture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about UNI-DUR vs ALBUTEROL SULFATE, answered by our medical review team.
UNI-DUR is a Methylxanthine Bronchodilator that works by UNI-DUR (theophylline) inhibits phosphodiesterase enzymes, leading to increased intracellular c AMP levels. This causes bronchodilation, anti-inflammatory effects (reduced eosinophil infiltration, decreased cytokine release), and enhanced diaphragmatic contractility. It also acts as a weak adenosine receptor antagonist.. ALBUTEROL SULFATE is a Beta-2 Adrenergic Agonist (Bronchodilator) that works by Beta-2 adrenergic receptor agonist resulting in bronchodilation via increased cyclic AMP synthesis and smooth muscle relaxation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between UNI-DUR and ALBUTEROL SULFATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of UNI-DUR is: 200-400 mg orally every 12 hours; maximum 800 mg daily.. The standard adult dose of ALBUTEROL SULFATE is: 2 puffs (90 mcg/puff) via metered-dose inhaler q4-6h as needed; or 2.5 mg via nebulization q4-6h as needed. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between UNI-DUR and ALBUTEROL SULFATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. UNI-DUR is classified as Category C. Pregnancy Category C. First trimester: no adequate studies, potential risk based on animal data. Second and third trimesters: may cause fetal harm including decreased uterine blood. ALBUTEROL SULFATE is classified as Category C. Pregnancy category C. Inhaled albuterol is not associated with major congenital malformations in first trimester. Second and third trimester use may cause fetal tachycardia, hyperg. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.